MX2014011045A - Metodo para seleccionar o identificar un sujeto para la terapia antagonista vib. - Google Patents
Metodo para seleccionar o identificar un sujeto para la terapia antagonista vib.Info
- Publication number
- MX2014011045A MX2014011045A MX2014011045A MX2014011045A MX2014011045A MX 2014011045 A MX2014011045 A MX 2014011045A MX 2014011045 A MX2014011045 A MX 2014011045A MX 2014011045 A MX2014011045 A MX 2014011045A MX 2014011045 A MX2014011045 A MX 2014011045A
- Authority
- MX
- Mexico
- Prior art keywords
- marker
- identifying
- selecting
- subject
- antagonist therapy
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000005557 antagonist Substances 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000003550 marker Substances 0.000 abstract 5
- 239000012472 biological sample Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000003205 genotyping method Methods 0.000 abstract 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 abstract 1
- 238000003018 immunoassay Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/304—Mood disorders, e.g. bipolar, depression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
Abstract
Se proporciona aquí un método para detectar una función del marcador del eje HPA en una muestra biológica. El método puede usarse para determinar si un paciente es un candidato adecuado para tratamiento con un antagonista V1B. El marcador HPA puede ser un marcador genómico, marcador no genómico, o una combinación de los mismos. Dependiendo del tipo de marcador HPA, el método de detección puede ser un inmunoensayo o genotipado, por ejemplo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610101P | 2012-03-13 | 2012-03-13 | |
| PCT/EP2013/055147 WO2013135769A1 (en) | 2012-03-13 | 2013-03-13 | Method for selecting or identifying a subject for v1b antagonist therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014011045A true MX2014011045A (es) | 2015-04-10 |
Family
ID=47846064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014011045A MX2014011045A (es) | 2012-03-13 | 2013-03-13 | Metodo para seleccionar o identificar un sujeto para la terapia antagonista vib. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130245038A1 (es) |
| EP (1) | EP2825891A1 (es) |
| JP (1) | JP2015512892A (es) |
| KR (1) | KR20140147837A (es) |
| CN (1) | CN104303060A (es) |
| AU (1) | AU2013231230A1 (es) |
| BR (1) | BR112014018717A8 (es) |
| CA (1) | CA2866220A1 (es) |
| HK (1) | HK1205789A1 (es) |
| MX (1) | MX2014011045A (es) |
| RU (1) | RU2014141059A (es) |
| SG (1) | SG11201405214YA (es) |
| WO (1) | WO2013135769A1 (es) |
| ZA (1) | ZA201406518B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140046407A1 (en) * | 2001-08-31 | 2014-02-13 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
| CN108845145A (zh) * | 2018-06-21 | 2018-11-20 | 大连民族大学 | 一种检测组氨酸激酶活性的方法 |
| CN109030828A (zh) * | 2018-06-21 | 2018-12-18 | 大连民族大学 | 一种检测组氨酸磷酸化蛋白的elisa检测试剂盒及检测方法 |
| AU2019384074B2 (en) * | 2018-11-20 | 2025-04-10 | Sparrow Pharmaceuticals, Inc. | Methods for administering corticosteroids |
| CN114624344A (zh) * | 2020-12-10 | 2022-06-14 | 中国科学院大连化学物理研究所 | 一种类固醇激素联合生物标志物及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1362776A (en) * | 1970-07-17 | 1974-08-07 | Wellcome Found | Immunological reagent |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| EP0273115B1 (en) | 1986-10-22 | 1994-09-07 | Abbott Laboratories | Chemiluminescent acridinium and phenanthridinium salts |
| US5241070A (en) | 1988-09-26 | 1993-08-31 | Ciba Corning Diagnostics Corp. | Nucleophilic polysubstituted aryl acridinium esters and uses thereof |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| JPH05504841A (ja) | 1990-09-14 | 1993-07-22 | バイオサイト・ダイアグノスティックス・インコーポレイテッド | リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途 |
| WO1992018866A1 (en) | 1991-04-10 | 1992-10-29 | Biosite Diagnostics Incorporated | Novel conjugates and assays for simultaneous detection of multiple ligands |
| AU1772992A (en) | 1991-04-10 | 1992-11-17 | Biosite Diagnostics Incorporated | Crosstalk inhibitors and their uses |
| ES2198823T3 (es) | 1992-03-30 | 2004-02-01 | Abbott Laboratories | Reactivos que permiten la deteccion y la cuantificacion de la tiroxina en muestras de fluido. |
| US5352803A (en) | 1992-03-30 | 1994-10-04 | Abbott Laboratories | 5(6)-methyl substituted fluorescein derivatives |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6925389B2 (en) | 2000-07-18 | 2005-08-02 | Correlogic Systems, Inc., | Process for discriminating between biological states based on hidden patterns from biological data |
| US6890763B2 (en) | 2001-04-30 | 2005-05-10 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons |
| AU2003239409A1 (en) | 2002-05-09 | 2003-11-11 | Surromed, Inc. | Methods for time-alignment of liquid chromatography-mass spectrometry data |
| WO2003097237A2 (en) * | 2002-05-13 | 2003-11-27 | Becton, Dickinson, And Company | Protease inhibitor sample collection system |
| WO2008137270A1 (en) * | 2007-05-04 | 2008-11-13 | H. Lundbeck A/S | Methods of diagnosing and monitoring of npy y5 based disorders |
| WO2009114627A2 (en) * | 2008-03-12 | 2009-09-17 | Ridge Diagnostics, Inc. | Inflammatory biomarkers for monitoring depression disorders |
| WO2009130232A1 (en) * | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors |
| CA2767458A1 (en) * | 2009-07-10 | 2011-01-13 | Bruce Acres | Biomarker for selecting patients and related methods |
-
2013
- 2013-03-13 WO PCT/EP2013/055147 patent/WO2013135769A1/en not_active Ceased
- 2013-03-13 AU AU2013231230A patent/AU2013231230A1/en not_active Abandoned
- 2013-03-13 SG SG11201405214YA patent/SG11201405214YA/en unknown
- 2013-03-13 KR KR1020147028639A patent/KR20140147837A/ko not_active Withdrawn
- 2013-03-13 HK HK15106312.1A patent/HK1205789A1/xx unknown
- 2013-03-13 RU RU2014141059A patent/RU2014141059A/ru not_active Application Discontinuation
- 2013-03-13 MX MX2014011045A patent/MX2014011045A/es unknown
- 2013-03-13 JP JP2014561437A patent/JP2015512892A/ja not_active Withdrawn
- 2013-03-13 US US13/798,360 patent/US20130245038A1/en not_active Abandoned
- 2013-03-13 CN CN201380014125.3A patent/CN104303060A/zh active Pending
- 2013-03-13 EP EP13708854.8A patent/EP2825891A1/en not_active Withdrawn
- 2013-03-13 CA CA2866220A patent/CA2866220A1/en not_active Abandoned
- 2013-03-13 BR BR112014018717A patent/BR112014018717A8/pt not_active IP Right Cessation
-
2014
- 2014-09-04 ZA ZA2014/06518A patent/ZA201406518B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140147837A (ko) | 2014-12-30 |
| HK1205789A1 (en) | 2015-12-24 |
| WO2013135769A1 (en) | 2013-09-19 |
| CN104303060A (zh) | 2015-01-21 |
| BR112014018717A2 (es) | 2017-06-20 |
| AU2013231230A1 (en) | 2014-08-07 |
| BR112014018717A8 (pt) | 2017-07-11 |
| SG11201405214YA (en) | 2014-10-30 |
| CA2866220A1 (en) | 2013-09-19 |
| JP2015512892A (ja) | 2015-04-30 |
| US20130245038A1 (en) | 2013-09-19 |
| RU2014141059A (ru) | 2016-04-27 |
| EP2825891A1 (en) | 2015-01-21 |
| AU2013231230A8 (en) | 2014-08-14 |
| ZA201406518B (en) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2519906A (en) | Methods and systems for detecting biological components | |
| EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
| EP2576833A4 (en) | METHOD AND DEVICE FOR THE POINT-OF-CARE DETECTION OF NUCLEIC ACID IN A SAMPLE | |
| WO2015094995A3 (en) | Gene signature biomarkers of tumor response to pd-1 antagonists | |
| MX366275B (es) | Metodos para detectar y medir la agregacion. | |
| WO2012149493A3 (en) | Hsp90 combination therapy | |
| GB2499519B (en) | User presence detection and event discovery | |
| MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
| EP4556576A3 (en) | Methods to diagnose and treat acute respiratory infections | |
| MX346624B (es) | Sistema y metodo para la deteccion de anormalidades en una muestra biologica. | |
| NZ594751A (en) | Method of diagnosis of infection by mycobacteria and reagents therefor | |
| NZ608384A (en) | Biomarkers of renal injury | |
| WO2011085163A3 (en) | Protein markers for lung cancer detection and methods of using thereof | |
| MX2014011045A (es) | Metodo para seleccionar o identificar un sujeto para la terapia antagonista vib. | |
| EP2637126A3 (en) | Method and apparatus for detecting vehicle | |
| PH12017500798A1 (en) | Pna probes, kits and methods for detecting human papillomavirus genotypes of human papillomavirus | |
| MX2015001961A (es) | Metodos y sistemas para ensayos. | |
| GB201206977D0 (en) | An enzyme detection device | |
| WO2015070191A3 (en) | Systems and methods for detection of genomic variants | |
| BRPI1009573A2 (pt) | método para avaliar uma condição artrítica em um sujeito, kit para detectar a presença de um auto-anticorpo, e, método para determinar o subtipo de artrite em um paciente. | |
| WO2012103337A3 (en) | Assays and methods to sequence microbes directly from immune complexes | |
| HK1204061A1 (en) | Methods and kits for detecting and diagnosing neurotrauma | |
| BR112017017878A2 (pt) | método, suporte e kit de coleta de ácido(s) nucleico(s) | |
| MX2015015023A (es) | Metodo para la determinacion de cobre libre. | |
| MX2021009281A (es) | Metodos de deteccion de legionella. |